Recursion Pharmaceuticals Inc (RXRX)
8.26
-0.61
(-6.88%)
USD |
NASDAQ |
May 31, 16:00
8.36
+0.10
(+1.21%)
After-Hours: 20:00
Recursion Pharmaceuticals Research and Development Expense (Quarterly): 67.56M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 67.56M |
| December 31, 2023 | 69.48M |
| September 30, 2023 | 70.01M |
| June 30, 2023 | 55.06M |
| March 31, 2023 | 46.68M |
| December 31, 2022 | 43.98M |
| September 30, 2022 | 40.84M |
| June 30, 2022 | 38.44M |
| March 31, 2022 | 32.44M |
| Date | Value |
|---|---|
| December 31, 2021 | 48.29M |
| September 30, 2021 | 33.25M |
| June 30, 2021 | 29.62M |
| March 31, 2021 | 24.11M |
| December 31, 2020 | 20.70M |
| September 30, 2020 | 16.54M |
| June 30, 2020 | 13.24M |
| March 31, 2020 | 12.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.84M
Minimum
Mar 2020
70.01M
Maximum
Sep 2023
39.00M
Average
38.44M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.523B |
| Viking Therapeutics Inc | 24.10M |
| Actinium Pharmaceuticals Inc | 6.635M |
| Macrogenics Inc | 46.03M |
| Marinus Pharmaceuticals Inc | 24.12M |